New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePinealon vs PT-141 (Bremelanotide)

Pinealon vs PT-141 (Bremelanotide)

Side-by-side comparison of key properties, dosing, and research.

Cognitive EnhancementAnti-Aging & Longevity
Pinealon
Sexual Health & Libido
PT-141 (Bremelanotide)
Summary
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation, designed to penetrate the blood-brain barrier and exert neuroprotective, neurogenic, and anti-aging effects by regulating pineal gland and brain cell function.
PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
Half-Life
Short (peptides rapidly degraded), but epigenetic/gene regulatory effects persist
2–3 hours
Admin Route
SubQ, Oral, Intranasal
SubQ
Research
Typical Dose
5–10 mg (oral) or 50–100 mcg (SC)
0.5–1.75 mg
Frequency
Once daily for 10 days
As needed (not daily)
Key Benefits
  • Neuroprotection against oxidative stress and hypoxia
  • Promotes neuronal regeneration and repair
  • Improves memory and cognitive function
  • Enhances sleep quality via melatonin regulation
  • Anti-aging effects on brain cells
  • May slow cognitive decline in neurodegeneration
  • Improves cerebrovascular circulation
  • Reduces neuroinflammation
  • Enhances sexual desire and libido in both men and women
  • Improves arousal through central nervous system activation
  • Effective for psychological erectile dysfunction
  • Works for female sexual arousal disorder
  • May improve sexual satisfaction and intensity
  • Fast-acting — effects within 45–60 minutes
  • FDA-approved for HSDD in premenopausal women
Side Effects
  • Excellent safety profile in clinical use
  • Rare: mild drowsiness
  • Transient mild headache at initiation
  • Injection site reaction (SC)
  • Nausea (most common — 40% of users in clinical trials)
  • Facial flushing and warmth
  • Transient blood pressure changes (typically increase then normalize)
  • Headache
  • +2 more
Stacks With